Palumbo Wealth Management LLC Purchases Shares of 38,335 Zura Bio Limited (NASDAQ:ZURA)

Palumbo Wealth Management LLC bought a new position in Zura Bio Limited (NASDAQ:ZURA) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 38,335 shares of the company’s stock, valued at approximately $156,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares during the last quarter. Forefront Analytics LLC grew its holdings in Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after purchasing an additional 7,531 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Zura Bio in the 2nd quarter valued at about $43,000. Finally, SG Americas Securities LLC purchased a new stake in Zura Bio in the 3rd quarter valued at about $62,000. 61.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZURA. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a report on Monday, October 21st. Finally, Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th.

Zura Bio Stock Down 2.6 %

Zura Bio stock traded down $0.12 during mid-day trading on Thursday, reaching $4.51. 54,623 shares of the company were exchanged, compared to its average volume of 324,880. The business has a fifty day moving average of $4.13 and a 200 day moving average of $4.06. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, analysts forecast that Zura Bio Limited will post -0.47 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 15.80% of the company’s stock.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.